Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 22;16(16):2922.
doi: 10.3390/cancers16162922.

Pathological Features Associated with Lymph Node Disease in Patients with Appendiceal Neuroendocrine Tumors

Salvador Rodriguez Franco  1 , Sumaya Abdul Ghaffar  1 , Ying Jin  2 , Reed Weiss  1 , Mona Hamermesh  1 , Andrii Khomiak  1 , Toshitaka Sugawara  1 , Oskar Franklin  1 , Alexis D Leal  3   4 , Christopher H Lieu  3   4 , Richard D Schulick  1   4 , Marco Del Chiaro  1   4 , Steven Ahrendt  1 , Martin D McCarter  1   4 , Ana L Gleisner  1
Affiliations

Pathological Features Associated with Lymph Node Disease in Patients with Appendiceal Neuroendocrine Tumors

Salvador Rodriguez Franco et al. Cancers (Basel). .

Abstract

This study aimed to evaluate the role of pathological features beyond tumor size in the risk of lymph node metastasis in appendiceal neuroendocrine tumors. Analyzing data from the national cancer database, we found that among 5353 cases, 18.8% had lymph node metastasis. Focusing on tumors smaller than 2 cm, a subject of considerable debate in treatment strategies, we identified lymphovascular invasion as one of the strongest predictors of lymph node disease. Interestingly, extension into the subserosa and beyond, a current factor in the staging system, was not a strong predictor. These findings suggest that careful interpretation of pathological features is needed when selecting therapeutic approaches using current staging systems.

Keywords: neuroendocrine tumors; nodal disease risk; practice patterns; predicted risk.

PubMed Disclaimer

Conflict of interest statement

None relevant to the study. COI outside the submitted work: Dr. Del Chiaro and Dr. Gleisner have received an industry grant (Haemonetics, Inc.) to conduct a multi-center study to evaluate the prognostic implications of TEG in pancreatic cancer. Dr. Del Chiaro is the principal investigator of an international multi-center study sponsored by Boston Scientific investigating the role of intra-operative pancreatoscopy in IPMN patients. Dr. Schulick is a coinventor of a patent licensed to DynamiCure (managed by the University of Colorado).

Figures

Figure 1
Figure 1
CONSORT diagram showing the cohort selection process.
See this image and copyright information in PMC

References

    1. Moris D., Tsilimigras D.I., Vagios S., Ntanasis-Stathopoulos I., Karachaliou G.S., Papalampros A., Alexandrou A., Blazer D.G., 3rd, Felekouras E. Neuroendocrine Neoplasms of the Appendix: A Review of the Literature. Anticancer Res. 2018;38:601–611. doi: 10.21873/anticanres.12264. - DOI - PubMed
    1. Rault-Petit B., Do Cao C., Guyétant S., Guimbaud R., Rohmer V., Julié C., Baudin E., Goichot B., Coriat R., Tabarin A., et al. Current Management and Predictive Factors of Lymph Node Metastasis of Appendix Neuroendocrine Tumors. Ann. Surg. 2019;270:165–171. doi: 10.1097/SLA.0000000000002736. - DOI - PubMed
    1. NCCN Guidelines® Updates: Neuroendocrine and Adrenal Tumors. J. Natl. Compr. Cancer Netw. 2021;19:xxii–xxx. doi: 10.6004/jnccn.2021.197glup. - DOI
    1. Niederle M.B., Hackl M., Kaserer K., Niederle B. Gastroenteropancreatic neuroendocrine tumours: The current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: An analysis based on prospectively collected parameters. Endocr. -Relat. Cancer. 2010;17:909–918. doi: 10.1677/ERC-10-0152. - DOI - PubMed
    1. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.-N., Rashid A., et al. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J. Clin. Oncol. 2008;26:3063–3072. doi: 10.1200/JCO.2007.15.4377. - DOI - PubMed

LinkOut - more resources